The Resurfacing of Bepridil Hydrochloride on the World Stage as an Antiarrhythmic Drug for Atrial Fibrillation [PDF]
Journal of Arrhythmia, 2009 Bepridil hydrochloride is a multiple ion channel blocker with relatively strong suppressive effects for various K+ channels. Recent clinical studies mainly done in Japan have revealed the eficacy of the agent for the management of atrial fibrillation (AF)
Yuji Nakazato, MD, PhD
doaj +6 more sources
Practice Variation in Establishing the Adequacy of Beta-Blockers as an Antiarrhythmic Agent in School-Aged Children and Adolescents [PDF]
CJC Open, 2020 Background: Beta-blockers (BBs) are commonly prescribed to manage arrhythmias in children and adolescents without any standardised approach to establish BB adequacy. We invited all Canadian pediatric cardiologists to participate in an anonymous survey to
Hilal Al Riyami, MD +3 more
doaj +2 more sources
ANTICHOLINERGIC ACTIVITY AND PHARMACOKINETIC PARAMETERS OF AGENT SS-68 WITH PROPERTIES OF CLASS III ANTIARRHYTHMIC DRUGS [PDF]
Research Results in Pharmacology, 2016 It was shown that the indole derivate SS-68 (50 and 250 µg/kg intravenous) in acute experiments on cats with neurogenic atrial fibrillation (AF) has a dose-dependent antiarrhythmic action which is associated with the neurotropic influence of this ...
Saida Bogus +4 more
doaj +7 more sources
Intra‐Operative Lidocaine Management in the Setting of Ventricular Tachycardia Storm: A Case Report [PDF]
Clinical Case ReportsEffective management of VT storm during catheter ablation involves discontinuation of antiarrhythmic agents to facilitate VT induction for mapping of the critical isthmus.
Cassandra Williams +4 more
doaj +2 more sources
Reappraising Use of Flecainide for Atrial Fibrillation and Ventricular Arrhythmias in Structural Heart Disease Patients [PDF]
MedicinaBackground: Flecainide, a class Ic antiarrhythmic agent, has long been contraindicated in structural heart disease (SHD) due to findings of the Cardiac Arrhythmia Suppression Trial (CAST).
Dimitrios Tsiachris +10 more
doaj +2 more sources
Antiarrhythmic properties of N-Deacetyllappaconitine Hydrochloride
Фармакокинетика и Фармакодинамика, 2022 The aim of the investigation was the research of the N-deacetyllappaconitine hydrochloride antiarrhythmic properties. It was found that the studied substance was effective on the cardiac arrhythmias model caused by aconitine hydrochloride, but does not ...
S. A. Kryzhanovskii +4 more
doaj +1 more source
Systematic review of the safety and efficacy of antazoline in the treatment of atrial fibrillation. [PDF]
Journal of Pharmacy & Pharmacognosy Research, 2022 Context: In the emergency department, patients with recent-onset atrial fibrillation are typically managed with intravenous antiarrhythmic agents. However, the currently used agents have a low efficacy and safety profile.
Raghad Aldulaymi, Ahmad Z. Al Meslamani
doaj
Российский кардиологический журнал, 2020 Aim. To individualize premature ventricular contraction (PVC) therapy in patients without structural cardiac changes by identifying potentially effective antiarrhythmic agents.Material and methods.
A. I. Olesin +3 more
doaj +1 more source
Frontiers in Tropical Diseases, 2023 The repurposing of approved drugs is an appealing method to fast-track the development of novel therapies for neglected diseases. Amiodarone and dronedarone, two approved antiarrhythmic agents, have been reported to have potential for the management of ...
Amanda F. Francisco +16 more
doaj +1 more source
Micro-RNA family that modulates fibrosis and uses thereof [PDF]
, 2017 The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response
Olson, Eric N., van Rooij, Eva
core +1 more source